Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Current Investments (2016 - 2026)

United Therapeutics' Cash & Current Investments history spans 17 years, with the latest figure at $2.9 billion for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 10.61% to $2.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 billion, a 10.61% decrease, with the full-year FY2025 number at $2.9 billion, down 10.61% from a year prior.
  • Cash & Current Investments hit $2.9 billion in Q4 2025 for United Therapeutics, up from $2.8 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for UTHR hit a ceiling of $3.3 billion in Q3 2024 and a floor of $1.7 billion in Q1 2021.
  • Historically, Cash & Current Investments has averaged $2.7 billion across 5 years, with a median of $2.8 billion in 2022.
  • Biggest five-year swings in Cash & Current Investments: surged 47.03% in 2022 and later dropped 16.8% in 2025.
  • Tracing UTHR's Cash & Current Investments over 5 years: stood at $1.9 billion in 2021, then soared by 47.03% to $2.8 billion in 2022, then rose by 5.47% to $3.0 billion in 2023, then grew by 9.11% to $3.3 billion in 2024, then decreased by 10.61% to $2.9 billion in 2025.
  • Business Quant data shows Cash & Current Investments for UTHR at $2.9 billion in Q4 2025, $2.8 billion in Q3 2025, and $3.0 billion in Q2 2025.